Back to the Top


Name: Octagam®
Synonyms: Intravenous Immunoglobulin, NewGam
Therapy Type: Immunotherapy (passive) (timeline)
Target Type: Amyloid-Related (timeline), Inflammation (timeline)
Condition(s): Alzheimer's Disease, Mild Cognitive Impairment
U.S. FDA Status: Alzheimer's Disease (Phase 2), Mild Cognitive Impairment (Phase 2)
Company: Octapharma


NewGam/Octagam® is an intravenous immunoglobulin preparation by the Switzerland-based company Octapharma. The rationale, as for other intravenous immunoglobulin preparations such as Gammagard® and Flebogamma, is that naturally occurring polyclonal autoantibodies against Aβ may be protective and are reduced in Alzheimer's disease (see Weksler et al., 2002).


The first trial of this IVIG preparation in Alzheimer's evaluated six different doses of Octagam 10 percent against two placebo comparators in a six-month trial of 58 people with mild to moderate AD. This multicenter Phase 2 trial has been completed. This trial missed its primary endpoint of change in plasma Aβ levels, and was negative for most of its secondary biomarker outcomes with the exception of a signal suggesting a benefit for cerebral metabolism. None of the doses tested showed any benefit for cognition or function (see Dodel et al, 2013; Feb 2013 news story).

A second, single-center Phase 2 study conducted at Sutter Institute for Medical Research in Sacramento, California, investigated the effects of this IVIG preparation infused every other week for two months in 52 people with amnestic MCI due to AD, with two years of follow up. Initial results on 28 patients assessed one year after treatment indicated a possible clinical benefit as measured by the Clinical Dementia Rating Sum of Boxes and an effect on brain atrophy as seen on MRI (see American Academy of Neurology 2013 abstract; Mar 2013 conference story).

Clinical Trial Timeline

  • Phase 2
  • Study completed / Planned end date
  • Planned end date unavailable
  • Study aborted
Sponsor Clinical Trial 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Octapharma NCT00812565
Sutter Health NCT01300728


Comments on this content

No Available Comments

Make a Comment

To make a comment you must login or register.


News Citations

  1. Research Brief: Octapharma IVIg Iffy in Phase 2 Trial
  2. Quick-and-Early IVIG Therapy: Hints of Promise

Paper Citations

  1. . Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2013 Mar;12(3):233-43. Epub 2013 Jan 31 PubMed.
  2. . Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol. 2002 Jul;37(7):943-8. PubMed.

External Citations

  1. American Academy of Neurology 2013 abstract

Further Reading

No Available Further Reading